中华血液学杂志2024,Vol.45Issue(1) :18-21.DOI:10.3760/cma.j.cn121090-20231007-00160

异基因造血干细胞移植治疗慢性粒-单核细胞白血病的临床结局

Clinical outcomes of allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia

张晓辉 周建英
中华血液学杂志2024,Vol.45Issue(1) :18-21.DOI:10.3760/cma.j.cn121090-20231007-00160

异基因造血干细胞移植治疗慢性粒-单核细胞白血病的临床结局

Clinical outcomes of allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia

张晓辉 1周建英1
扫码查看

作者信息

  • 1. 北京大学人民医院、北京大学血液病研究所、国家血液系统疾病临床医学研究中心、造血干细胞移植北京市重点实验室,北京 100044
  • 折叠

摘要

慢性粒-单核细胞白血病(CMML)是一种来源于骨髓造血干细胞的克隆性疾病,预后较差.异基因造血干细胞移植(allo-HSCT)是可治愈CMML的方法之一.患者移植后结局受疾病特征和患者共病等多种因素影响.根据现有预后分层系统,筛选出适合移植的CMML患者并早期移植,有利于其长期生存.医生可根据新开发的移植预后模型评估移植后CMML患者的生存情况并作出针对性的医疗决策.

Abstract

Chronic myelomonocytic leukemia(CMML)is a clonal disease derived from bone marrow hematopoietic stem cells,with a poor prognosis.Allogeneic hematopoietic stem cell transplantation(allo-HSCT)is one of the curable methods for CMML.The outcome of patient transplantation is influenced by vari-ous factors such as disease characteristics and comorbidities.Based on the existing prognostic stratification sys-tem,screening suitable CMML patients for transplantation and early transplantation is beneficial for their long-term survival.Doctors can evaluate the survival status of CMML patients after transplantation based on the newly developed transplant prognosis model and make targeted medical decisions.

关键词

慢性粒-单核细胞白血病/异基因造血干细胞移植/临床结局

Key words

Chronic myelomonocytic leukemia/Allogeneic hematopoietic stem cell transplanta-tion/Clinical outcomes

引用本文复制引用

出版年

2024
中华血液学杂志
中华医学会

中华血液学杂志

CSTPCDCSCD北大核心
影响因子:1.17
ISSN:0253-2727
参考文献量28
段落导航相关论文